<div id="readability-page-1"><p>In a report released yesterday, Joshua Schimmer from Cantor Fitzgerald maintained a Buy rating on Invivyd, with a price target of <span id="expert-recommendation-target">$10.00</span>.</p><h3>Meet Your ETF AI Analyst</h3><ul><li> Discover how TipRanks' <i>ETF</i> AI Analyst  can help you make smarter investment decisions </li><li>   Explore ETFs TipRanks' users love  and see what insights the <b><i>ETF</i> AI Analyst</b> reveals about the ones you follow.</li></ul> <p>Schimmer covers the Healthcare sector, focusing on stocks such as Cabaletta Bio, Palvella Therapeutics, and Rocket Pharmaceuticals. According to TipRanks, Schimmer has an average return of <span>15.5%</span> and a 52.43% success rate on recommended stocks. </p> <p>The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Invivyd with a $10.00 average price target.</p></div>

IVVD

<p>Cantor Fitzgerald analyst Joshua Schimmer has maintained a Buy rating on Invivyd (IVVD) with a price target of $10.00. Schimmer, who specializes in the Healthcare sector, has an average return of 15.5% and a success rate of 52.43% on his stock recommendations. The overall analyst consensus for Invivyd is a Moderate Buy, also with a $10.00 average price target.</p>

Cantor Fitzgerald Keeps Their Buy Rating on Invivyd (IVVD)